Filip Dubovsky - Dec 14, 2023 Form 4 Insider Report for NOVAVAX INC (NVAX)

Role
President, R&D
Signature
/s/ Mark Casey, Attorney-in-Fact
Stock symbol
NVAX
Transactions as of
Dec 14, 2023
Transactions value $
$8,336
Form type
4
Date filed
12/18/2023, 05:00 PM
Previous filing
Nov 7, 2023
Next filing
Mar 26, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NVAX Common Stock Options Exercise $16.1K +2.83K +5.42% $5.69 55.2K Dec 14, 2023 Direct
transaction NVAX Common Stock Tax liability -$7.78K -1.37K -2.48% $5.69 53.8K Dec 14, 2023 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NVAX Restricted Stock Units Options Exercise $0 -2.83K -100% $0.00* 0 Dec 14, 2023 Common Stock 2.83K Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock.
F2 The RSUs subject to this grant under the Plan vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment with the Company through such vesting date.